Intravenous Thyroxine for Heart-Eligible Organ Donors

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 838 participants.

Also called NCT04415658

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 838 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04415658
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04415658. Randomized; no masking; primary purpose treatment. Start 2020-12-01 (actual); primary completion 2022-11-06 (actual). Results posted on 2024-01-10.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Intravenous Thyroxine for Heart-Eligible Organ Donors
Condition
Brain Death
Condition
Heart Failure
Intervention (Drug)
Thyroxine
Intervention (Drug)
Saline
Lead sponsor
Washington University School of Medicine (class: other)
Collaborator
Mid-America Transplant (class: other)

Record details

Record id
cardio:ct-nct04415658
Content hash
a6f4d97874268bc0dddeaf7e91b83ff9156fd6ab836e89fe9abfb978db70e0ee